AbCellera Biologics Inc. (ABCL) Stock Score, Valuation & Financial Research
AbCellera Biologics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 18/100.
Quick answer for ABCL
AbCellera Biologics Inc. currently has a Wall Street Score of 18/100. The stored market price is $11.17. Its financial score is 26/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What AbCellera Biologics Inc. does
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL financial snapshot
- Wall Street Score:
- 18/100
- Current price:
- $11.17
- Market capitalization:
- $3.41B
- Revenue:
- $66.2M
- Net income:
- $-164.7M
- Free cash flow:
- $-174.1M
- Cash:
- $120.1M
- Total debt:
- $135.6M
- EPS:
- -0.54
- Financial score:
- 26/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-174.1M, showing cash burn in the current stored period.
- The balance sheet shows $120.1M of cash versus $135.6M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 26/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ABCL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.